Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

FDA Grants Fast Track Designation to VCN-01 in Metastatic Pancreatic Cancer

May 23rd 2024

VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.

Exploring Vaccine Approaches for Immunoprevention in Low-Grade Glioma

May 22nd 2024

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.

JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis

May 22nd 2024

Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

May 21st 2024

Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.

Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis

May 21st 2024

Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

May 20th 2024

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

May 16th 2024

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Lower Neighborhood Opportunity Is Linked With Increased Stress, Risk of All-Cause Mortality in Breast Cancer

May 15th 2024

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

FDA Approves HPV Self-Collection Test for Cervical Cancer

May 15th 2024

The FDA has approved one of the first HPV self-collection solutions, which can be used to identify women who are at risk of developing cervical cancer.

Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma

May 14th 2024

R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.

Identifying Individual Social Determinants of Health Could Reduce Barriers to Breast Cancer Care

May 14th 2024

Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.

Pirtobrutinib Transforms SOC in Later-Line CLL/SLL

May 14th 2024

Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.

Adjuvant Immunotherapy Represents Potential New Frontier in CSCC

May 13th 2024

Axel Hauschild, MD, elucidates the varying role of treatment for both cutaneous cell carcinoma and basal cell carcinoma that are seen globally.

Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma

May 13th 2024

The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.

Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD

May 12th 2024

Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.

Mohty Shares Key Takeaways From the 50th Annual EBMT Meeting, Highlighting Advances in GVHD

May 9th 2024

Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EBMT Meeting, focusing on ongoing efforts within the GVHD treatment arena.

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

May 9th 2024

Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.

Action is Key to Continue to Break Down Barriers for Equitable Cancer Care

May 8th 2024

Experts from the University of Wisconsin Health discuss ongoing barriers to equitable cancer care and ways to drive change.

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

Enfortumab Vedotin/Pembrolizumab vs Nivolumab/Chemo: Selecting a Frontline Therapy for Advanced Urothelial Carcinoma

May 7th 2024

Thomas Flaig, MD, discusses how enfortumab vedotin/pembrolizumab and nivolumab/chemotherapy fit in the frontline treatment of advanced urothelial carcinoma.